Johnson & Johnson (JNJ)
NYSE • Healthcare
November 17, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Johnson & Johnson keeps $1 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Jan 26
in 69 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Johnson & Johnson’s adjusted EPS topped expectations while revenue came in line, based on preliminary results for the third fiscal quarter of 2026 that were reported October 13, 2026. Revenue rose 5.9% to about $25.4 billion (up from roughly $24.0 billion a year ago), with performance driven by its Innovative Medicine and MedTech franchises, while the consensus comparison showed revenue of $25.399 billion versus the $25.383 billion estimate (+0.1%, in line). Adjusted EPS of $2.59 was down 7.5% from $2.80 a year ago but topped the $2.52 estimate (+2.8%). On profitability, gross margin stood at about 73% and operating margin was roughly 25%, with gross profit of about $18.5 billion and operating income of around $6.4 billion providing most of the earnings support. For the next period, consensus calls for EPS of $2.93 on revenue of $26.423 billion.
About Johnson & Johnson
Johnson & Johnson develops and sells healthcare products across pharmaceuticals and medical technology, with shares listed on the NYSE under JNJ. In FY2025 it generated $94.2 billion in revenue. The company operates in healthcare as a maker of medicines and care-delivery products for hospitals, medical professionals, and retail channels.
Today's Snapshot
The day ended with JNJ 1.3% lower at 278.75, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level. Johnson & Johnson reportedly held talks with Ollin Biosciences, a biotech company, about a possible deal.
Trading Volume
Below 10d avg (7.5M)
4.3M
vs S&P 500 Today
Inline with Market
+0.01%
Updated: November 17, 2026 at 21:10 UTC
JNJ Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$248.62 - $279.17Buy
- RSI (14)56.43Neutral
- Stochastic %K (14, 3, 3)71.44Neutral
- MACD Level (12, 26)5.09Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.